Metformin and Gliburidson drugs for oral use effective to maintain glycemic control of gestational diabetes (DG).But some adverse effects are more serious with glibrid, according to a Chinese study.
As explained by Dr. Zhong-Ning Zhu via e-mail, "Glyburid was associated with a greater increase in neonatal maternal weight, as well as the incidence of neonatal hypoglycemia and macrosomia, which metformin."
The ZHU team, from the Hebei Medical University, Shijiazhuang, made a network analysis with 18 randomized reheosclinic trials with oral use drugs or insulin drugs.
The number of participants varied between two tens to more 700, according to the team in Journal of Clinical Endocrinology & Amp;Metabolism.
"There was no significant difference in maternal glucose values in fasting or HBA1C among patients with DG treated with insulin, metformin and glibrid," Zhu said.
But metformin was associated with a lower average difference in maternal weight versus insulin (-1.49 kg).The same happened with gestational age (-0.16 weeks), although the incidence of premature delivery increased (or = 1.63).
All differences were statistically significant.
The glibuid was associated with significant increases from the neonatal (131 g) and the incidence of neonatal hypoglycemia (or = 2.64) and macrosomia (or = 3.09).
"Although it was not shown that some of these drugs cause long -term damage to babies who were exposed, there are no prolonged studies versus control in humans or animal models," the team said.
The use of oral antidiabetics would only be therapeutically insufficient, so that doctors "should guide their patients about the risks of not achieving optimal glucose control with a single medication."
A team of Sweden recently discovered that the use of gliburida to treat the DG is associated with a greater risk of damaging newborns than insulin (see Reutershealth news of March 30, 2015).
Source: J Clin Endocrinol Metab 2015.